Osteoporosis Treatment Guidelines

First-Line Pharmacologic Treatment

The American College of Physicians recommends starting oral bisphosphonates, such as alendronate 70 mg weekly or risedronate 35 mg weekly, as first-line therapy for postmenopausal women and older adults with osteoporosis, combined with calcium 1,200 mg daily and vitamin D 800 IU daily, based on high-certainty evidence showing a 50% reduction in hip fractures and 47-56% reduction in vertebral fractures over 3 years 1, 2, 3
Oral bisphosphonates are the mandatory initial treatment, with specific options including alendronate 70 mg once weekly, risedronate 35 mg once weekly, and zoledronic acid 5 mg IV annually for patients unable to tolerate oral formulations 1, 3

The American College of Rheumatology recommends that all patients receive calcium 1,200 mg daily and vitamin D 800 IU daily, as pharmacologic therapy is significantly less effective without adequate supplementation 1, 3, 4, 5
Target serum vitamin D level should be ≥20 ng/mL 4, 5

The American College of Physicians recommends denosumab 60 mg subcutaneously every 6 months as second-line therapy for patients with contraindications to or intolerance of bisphosphonates 1, 2, 3
IV bisphosphonates, such as zoledronic acid, are preferred over denosumab if oral bisphosphonates are not tolerated, due to higher risk profile with denosumab in immunosuppressed patients 4, 5, 6

The American College of Physicians recommends considering teriparatide, abaloparatide, or romosozumab for very high-risk patients, such as those with recent vertebral fractures, hip fracture with T-score ≤-2.5, or multiple fractures 1
Patients initially treated with anabolic agents must transition to an antiresorptive agent after discontinuation to preserve gains and prevent serious rebound multiple vertebral fractures 1, 2, 3

The American College of Physicians recommends an initial treatment duration of 5 years with bisphosphonates, after which fracture risk should be reassessed to determine if continued therapy is warranted 1, 3
Bone density should not be monitored during the initial 5-year treatment period, as bisphosphonates reduce fractures even without BMD increases 1, 3

The American College of Rheumatology recommends weight-bearing exercise and resistance training, such as squats and push-ups, for all patients 5
Smoking cessation is mandatory, and alcohol intake should be limited to 1-2 alcoholic beverages per day 4, 5, 3
Maintaining a healthy body weight is essential, as excessively low body weight increases fracture risk 4, 5

High-certainty evidence shows that bisphosphonates cause no difference in serious adverse events compared to placebo at 2-3 years 1, 3
Common adverse effects include mild upper GI symptoms, influenza-like symptoms, myalgias, arthralgias, and headaches 3
Rare but serious adverse effects include osteonecrosis of the jaw and atypical femoral fractures, which increase with prolonged use beyond 5 years 1, 3

The American College of Physicians strongly recommends avoiding menopausal estrogen therapy, estrogen plus progestogen therapy, or raloxifene for osteoporosis treatment due to unfavorable benefit-harm balance 1, 3
Raloxifene may only be considered for postmenopausal women in whom none of the preferred medications are appropriate 4, 5, 6

The American College of Physicians recommends using the same treatment algorithm for men with primary osteoporosis: bisphosphonates first-line, denosumab second-line 2
Limited evidence is available for males, so recommendations are extrapolated from postmenopausal women trials with low-certainty evidence 2

The American College of Physicians recommends not prescribing calcium and vitamin D alone for established osteoporosis, as this is insufficient and requires pharmacologic therapy 1, 3
Brand-name medications should not be used when generic bisphosphonates are available and equally effective 1, 2
Bisphosphonates should not be continued indefinitely without reassessing fracture risk at 5 years due to increasing harm-to-benefit ratio 1, 3
Denosumab should not be stopped without transitioning to bisphosphonates to prevent rebound fractures 1, 3

Initiate oral bisphosphonate therapy (either alendronate 70 mg weekly or risedronate 35 mg weekly) together with calcium 1,200 mg daily and vitamin D 800 IU daily as the first‑line regimen for adults who have sustained a tibial‑fibular fracture from a low‑energy fall, regardless of the presence of surgical implants. 7
In this population, the fracture is classified as a fragility fracture, indicating a high subsequent fracture risk and justifying immediate osteoporosis treatment. 7

If oral bisphosphonates cannot be used (e.g., due to gastrointestinal intolerance), denosumab 60 mg subcutaneously every 6 months is recommended as a second‑line option, but only after both oral and intravenous bisphosphonates are deemed contraindicated or intolerable. 7

After an initial 5‑year course of bisphosphonates, reassess fracture risk (considering ongoing risk factors, any new fractures, or notable loss of bone mineral density). If the patient remains at moderate‑to‑high risk, continuation of bisphosphonate therapy for a total of 7–10 years is advised. 8

Prolonged bisphosphonate exposure beyond 5 years is associated with rare but serious adverse events, specifically osteonecrosis of the jaw and atypical femoral fractures; these risks increase with longer treatment duration. 7